Table 2.
Univariable logistic regression analysis of factors associated with achieving a glucocorticoid dose ≤ 4 mg/day.
| Variable | OR | 95% CI | p |
|---|---|---|---|
| Age at onset | 1.00 | 0.969, 1.04 | 0.91 |
| Sex | 1.13 | 0.431, 2.96 | 0.81 |
| Disease duration at the last observation (months) | 0.999 | 0.992, 1.01 | 0.68 |
| ANCA positivity at onset | 1.10 | 0.403, 2.99 | 0.86 |
| ANCA titer at onset (U/ml) | 0.999 | 0.997, 1.00 | 0.54 |
| FFS at onset | 1.80 | 0.973, 3.33 | 0.061 |
| BVAS at onset | 0.992 | 0.927, 1.06 | 0.81 |
| White blood cell counts at onset (/μl) | 1.00 | 1.00, 1.00 | 0.25 |
| Absolute eosinophil count at onset (/μl) | 1.00 | 1.00, 1.00 | 0.26 |
| CRP at onset (mg/dl) | 0.973 | 0.854, 1.11 | 0.68 |
| IgE at onset (U/ml) | 1.00 | 1.00, 1.00 | 0.39 |
| mPSL pulse at onset | 0.405 | 0.141, 1.17 | 0.094 |
| Initial GC dose, PSL equivalent (mg/day) a) | 0.999 | 0.969, 1.03 | 0.95 |
| Initial GC dose, PSL equivalent (mg/kg) a) | 2.02 | 0.266, 15.4 | 0.50 |
| Mepolizumab | 3.30 | 1.18, 9.19 | 0.022* |
| Clinical manifestations at onset | |||
| Cutaneous manifestations | 2.53 | 0.928, 6.88 | 0.070 |
| Mucous membranes/eyes | 0.375 | 0.0397, 3.55 | 0.39 |
| Asthma | 0.149 | 0.031, 0.718 | 0.018* |
| ENT manifestations | 1.04 | 0.372, 2.88 | 0.95 |
| Cardiovascular involvement | 2.22 | 0.538, 9.12 | 0.27 |
| Gastrointestinal involvement | 5.25 | 0.517, 53.3 | 0.16 |
| Renal involvement | 0.859 | 0.254, 2.90 | 0.81 |
| Peripheral neuropathy | 0.982 | 0.327, 2.95 | 0.97 |
*P<0.05. a) Initial GC oral daily dose during remission induction therapy.
ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis activity score; CI, confidence interval; CRP, C-reactive protein; ENT, ear, nose, and throat; FFS, five-factor score; GC, glucocorticoid; IgE, immunoglobulin E; mPSL, methylprednisolone; OR, odds ratio; PSL, prednisolone.